Please login to the form below

tralokinumab

This page shows the latest tralokinumab news and features for those working in and with pharma, biotech and healthcare.

AZ’s Fasenra hit by COPD trial failure

IL-13 inhibitor tralokinumab has been abandoned after three failed late-stage trials, however, while AZ also has an Amgen-partnered thymic stromal lymphopoietin (TSLP) targeting antibody - tezepelumab - in phase III

Latest news

AZ gets EMA green light for severe asthma drug Fasenra

Prospects for IL-13 inhibitor tralokinumab look terminal after three failed late-stage trials, however, and AZ also has an Amgen-partnered thymic stromal lymphopoietin (TSLP) targeting antibody - tezepelumab - in phase
AZ prices severe asthma drug Fasenra below competition

Prospects for IL-13 inhibitor tralokinumab look rocky after two failed late-stage trials, elevating the importance of Fasenra in those plans.
AZ severe asthma drug benralizumab backed by CHMP

Benralizumab has assumed much greater importance for the company since IL-13 inhibitor tralokinumab - another severe asthma candidate - failed two phase III trials.
Setback for AZ as tralokinumab flunks asthma trial

Puts more pressure on AZ’s benralizumab to reach its potential. AstraZeneca’s hopes of bringing severe asthma candidate tralokinumab to market look rocky after it failed two phase III trials. ... Tralokinumab is an inhibitor of interleukin-13 (IL-13),
Roche out-licenses lebrikizumab rights to Dermira

Disappointing results with other IL-13-targeting drugs in asthma - including Pfizer's anrukinzumab and AstraZeneca's tralokinumab - undermined confidence in the approach.

More from news
Approximately 4 fully matching, plus 16 partially matching documents found.

Latest Intelligence

Leo has its eyes on the prize

Its landmark partnership with AstraZeneca and the launch of Kyntheum, the fully-human monoclonal antibody targeting psoriasis, and the phase III hope of tralokinumab for atopic dermatitis are part of an
2016: The year when deal-makers took stock?

Out-partnering deals included the $1.1bn licence to LEO for tralokinumab in skin diseases and the $1bn divestment to Pfizer of its late-stage small molecule anti-infective business.
Deal Watch July 2016

AstraZeneca is developing tralokinumab for severe asthma, where it is in phase III development, and has recently completed a phase IIb study in patients with atopic dermatitis. ... Acquisition. 1, 530. AstraZeneca/ Leo Pharma. Tralokinumab (anti-IL-13)

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Account Director – UK Office: Excellent salary and benefits

Account Manager – Healthcare advertising: Salary TBC

Senior Medical Writer: Competitive salary plus benefits

Client Services Director- Flexible Working: Negotiable

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Events Executive: DOE

Subscribe to our email news alerts

PMHub

Add my company

Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...